Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups

1. Bardia, A.
2. Cortés, J.
3. Bidard, F.-C.
4. Neven, P.
5. Garcia-Sáenz, J.
6. Aftimos, P.
7. O'Shaughnessy, J.
8. Lu, J.
9. Tonini, G.
10. Scartoni, S.
11. Paoli, A.
12. Binaschi, M.
13. Wasserman, T.
14. Kaklamani, V.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1158/1078-0432.CCR-24-1073 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus